Last reviewed · How we verify
TQH2722 injection
TQH2722 injection is a Small molecule drug developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. It is currently in Phase 3 development.
TQH2722 injection's mechanism is not publicly available.
TQH2722 injection is being studied in clinical trials for the treatment of Atopic Dermatitis, Chronic Rhinosinusitis, and Seasonal Allergic Rhinitis. The exact mechanism of TQH2722 injection is currently unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TQH2722 injection |
|---|---|
| Sponsor | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action of TQH2722 injection.
Approved indications
Common side effects
Key clinical trials
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis (PHASE2)
- Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps (PHASE2)
- Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis (PHASE2)
- A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. (PHASE2)
- To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (PHASE3)
- A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQH2722 injection CI brief — competitive landscape report
- TQH2722 injection updates RSS · CI watch RSS
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. portfolio CI
Frequently asked questions about TQH2722 injection
What is TQH2722 injection?
How does TQH2722 injection work?
Who makes TQH2722 injection?
What development phase is TQH2722 injection in?
Related
- Manufacturer: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing